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ABSTRACT 
 
Objectives: Vaccination is a key strategy to reduce infection risk in RA patients 
and is advocated in internationally recognised rheumatology society guidelines. 
The aim was to evaluate to the impact of anti-rheumatic drugs on influenza and 
pneumococcal vaccine immunogenicity. 
 
Methods: We conducted a systematic literature review and meta-analysis 
comparing the humoral response to influenza (pandemic and seasonal trivalent 
subunit vaccines) and pneumococcal (PPV23, PCV-7, PCV-13) vaccination in adult 
RA patients treated with anti-rheumatic drugs. Vaccine immunogenicity was 
assessed by seroprotection rates measured 3 to 6-weeks post immunisation. Risk 
ratios and 95% CIs were pooled. 
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Results: Nine studies were included in the meta-analysis (7 studies investigating 
anti-rheumatic drug exposures and influenza humoral response, 2 studies 
investigating pneumococcal vaccine response). Influenza vaccine responses to all 
subunit strains (H1N1, H3N2, B strain) were preserved with methotrexate and TNF 
inhibitor drug exposure. Methotrexate but not TNF inhibitor drug exposure was 
associated with reduced 6B and 23F serotype pneumococcal vaccine response 
(risk ratio 0.42, 95% CI 0.28 to 0.63) vs. 0.98 (95% CI 0.58 to 1,67)), however 
limited data were available to draw any firm conclusions. Combination of 
methotrexate with tocilizumab or tofacitinib was associated with reduced 
pneumococcal and influenza vaccine responses. 
 
Conclusions: Anti-rheumatic drugs may negatively impact humoral responses to 
vaccination as evidenced by pneumococcal responses with methotrexate 
exposure, however they are safe and should not preclude immunisation against 
vaccine preventable disease. Vaccination should be considered in all RA patients 
and encouraged as part of routine care. Systematic review registration number: 
PROSPERO 2016: CRD42016048093. 
 
 
INTRODUCTION 
 
Rheumatoid arthritis (RA) patients are at an increased risk of infection 
compared to healthy subjects (1). The is due to a multifactorial complex interaction 
between inherent immune dysfunction, comorbidity, disease activity and 
immunosuppression (2). Highly targeted therapies (including Tumour Necrosis Factor 
inhibitor drugs (TNFi), Rituximab (RTX), Tocilizumab (TOC) and Abatacept (ABA) and 
most recently Tofacitinib (TOF)) have revolutionised RA management, however the 
infection risk associated with these drugs is a concern for clinicians and 
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patients. 
 
British Society for Rheumatology (BSR), European League Against 
Rheumatism (EULAR) and American College of Rheumatology (ACR) guidelines (3, 
 
4) recommend vaccination against vaccine preventable diseases (including 
influenza and pneumococcal infections). The literature supports the safety of 
common vaccinations in autoimmune disease and the Swedish EIRA study has 
reported no increased risk of developing RA following common vaccination (5, 6). 
 
In the U.K., routine vaccination schedules advise annual influenza and 
single PPV23 vaccination in individuals over the age of 65 or anybody with chronic 
comorbid illness including pulmonary, cardiac, renal or liver disease. 
Immunocompromised patients (of any cause) should also be offered vaccination. 
Historically uptake of vaccination in RA populations has been poor, particularly with 
pneumococcal vaccination (7, 8). The reasons may include a lack of awareness 
about the indications for vaccination amongst primary or secondary care providers, 
concerns pertaining to vaccine safety, efficacy or fear of worsening disease activity. 
 
The seasonal influenza vaccine is an inactivated trivalent subunit vaccine 
comprised of 3 viral antigens (2 ‘A’ strains, H1N1 and H3N2 and a single ‘B’ strain). 
The pandemic influenza vaccine (pH1N1) is utilised when necessary. In the U.K., two 
commercially available pneumococcal vaccines are currently used, a 23-valent 
polysaccharide vaccine (PPV23) and a 13-valent conjugate vaccine (PCV-13) which 
superseded a 7-valent conjugate vaccine (PCV-7) in 2010. Vaccine immunogenicity 
depends upon vaccine type and vaccine strain but post-vaccination antibody (Ab) titres 
to assess vaccine response are not routinely measured (9). 
 
EULAR guidance recommends that influenza and pneumococcal vaccines 
should be administered prior to immunosuppression. Vaccination can be 
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administered during non-biologic disease modifying anti-rheumatic drugs 
(nbDMARDs) and TNFi treatment but ideally prior to commencing RTX (3). This is 
because immunosuppression may blunt serological responses to vaccination. 
 
The rationale for undertaking this systematic review of the literature and meta-
analysis was to evaluate the impact of immunosuppressive drugs commonly used in 
RA on humoral immune responses to influenza and pneumococcal vaccination. 
 
 
MATERIALS AND METHODS 
 
The study was conducted in accordance with the preferred reporting items 
for systematic reviews and meta- analysis guidelines (10). The systematic review 
was registered with the international prospective register of systematic reviews 
(registration number: PROSPERO 2016: CRD42016048093). Ethics board 
approval was not required for this study. 
 
Search strategy and information sources 
 
The literature was searched systematically by two investigators (S.S. and K.B.) 
using MEDLINE and EMBASE databases. The vaccines of interest were influenza 
(seasonal, pH1N1) and pneumococcal (PCV-7, PCV-13, PPV23) vaccines. The search 
terms were ‘inflammatory arthritis’ or ‘rheumatoid arthritis’ and ‘immunisation’ or 
‘vaccination’ or ‘vaccine’ or ‘influenza’ or ‘pneumovax’ or ‘prevenar’. 
 
The search was undertaken in 6
th
 October 2016 and re-run on 12
th
 October 2017 
prior to the final analysis to identify further studies that could be retrieved for 
analysis. 
 
Eligibility criteria and study selection 
 
English language publications of prospective cohort studies and randomised 
 
control trials published between 1st January 2000 and 6
th
  October 2016 were 
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sought. Case reports and conference abstracts were excluded. RA patients aged 
over 18 years treated with anti-rheumatic drugs who had received influenza and/or 
pneumococcal vaccines were considered. Alternative diagnoses of inflammatory 
arthritis were excluded. Drugs exposures studied included methotrexate (MTX), 
TNFi, RTX, TOC, ABA and TOF. Other nbDMARDs were not studied. 
 
The primary outcome of interest was evidence of seroprotection (SP) as a 
surrogate measure of vaccine immunogenicity, classified by anti-rheumatic drug 
exposure. Seroconversion (SC) and/or SR were considered if SP rates were not 
published or calculable from the data presented. For influenza vaccination, SP was 
considered as a post-vaccination Ab titre measured by haemagglutination inhibition 
assay (HI) of ≥ 1:40, SR or SC a 4-fold increase in post vaccine Ab titre. For this 
study and in the absence of an accepted universal correlate of vaccine protection, 
a post-vaccination Ab titre of 1 mcg/ml was used as a marker of likely protection 
following pneumococcal vaccination, SR was defined as ≥2-fold increase in post-
vaccine Ab titres. Studies reporting only on geometric mean titres (GMT), 
opsonisation index (OI) or Ab response rates were excluded. Vaccine response 
was assessed between 3 and 6-weeks post influenza and pneumococcal 
vaccination. Healthy controls (HC) or RA subjects not taking anti-rheumatic or 
immunosuppressive therapies served as the comparator groups. 
 
Titles and abstracts of studies retrieved using the search strategy detailed 
above and those from additional sources (including reference lists of selected 
publications) were screened independently (by S.S. and K.B.). The full text of the 
potential studies for inclusion were retrieved and assessed for eligibility. The full 
electronic search strategy is available in the supplementary material accompanying 
this manuscript. 
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Data collection process and outcomes and quality assessment 
 
Data were extracted independently (by S.S. and K.B.). Disagreements over 
study eligibility, quality (as assessed using the Newcastle-Ottawa Score (NOS) for 
cohort studies) or risk of bias were resolved through discussion with a third 
reviewer (J.G.) where necessary. Details of the assessment of study quality are 
available in the supplementary material (supplementary Table 1). Data collated 
included the source (main author, journal, publication date), study design, 
vaccination intervention, anti-rheumatic drug exposure and patient characteristics 
(age, disease duration, disease activity, quality of life measures where available). 
SP, SR and SC rates were documented or calculated from data available. 
 
Data synthesis and statistical analysis 
 
Analyses were performed using Review Manager software version 5.3 
(Cochrane Collaboration, Oxford, U.K.). Sensitivity analyses compared vaccine 
response within immunosuppression class and descriptive analysis was 
undertaken to assess the effect of vaccine response in patients with RA by drug 
class. Summary data rather than individual level data were aggregated for 
quantitative analyses. Summary estimates of response were tabulated and 
compared using a meta-synthesis approach with forest plots. 
 
 
RESULTS 
 
Literature search and study characteristics 
 
The initial search strategy yielded 3893 articles for screening which was 
reduced to 47 after application of filters and screening of titles and abstracts. Nine 
studies were selected for inclusion (7 influenza (seasonal or pandemic) and 2 
pneumococcal vaccine studies). The search strategy is detailed in Figure 1. The 
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characteristics of studies examining influenza and pneumococcal vaccine 
immunogenicity are detailed in Tables 1 and 2, forest plots for the risk ratio (RR) of 
response rates for influenza vaccine strains and pneumococcal serotype 
responses separated by anti-rheumatic drug exposure (MTX or TNFi) are 
represented in Figures 2 and 3. All studies included in the meta-analyses were 
prospective cohort studies. There was good agreement between reviewers on the 
quality of included studies; all included studies scored between 5 and 7 on the 
NOS scale (see supplementary material Table 1). It was not possible to evaluate 
the impact of RTX, ABA, TOC or TOF in meta-analyses either due to an absence 
HC or comparator groups, unpublished vaccine response rates or limited number 
of studies available for analysis. These studies are discussed further as part of a 
narrative review. Studies examining the immunogenicity of pneumococcal vaccine 
in the context of anti-rheumatic drug exposures have been included in a 
supplementary material (supplementary Table 2). 
 
Influenza vaccine responses 
 
MTX and influenza vaccination response 
 
Five studies including 787 subjects (350 RA patients, 437 controls) 
assessed MTX exposure and influenza vaccine humoral responses (11-15). Three 
studies assessed the response to pH1N1 influenza vaccination, these results were 
pooled with seasonal influenza H1N1 responses (15-17). MTX exposure was not 
associated with reduced SP responses to H1N1 (pooled (RR) 0.88 [95% 
Confidence Interval (CI) 0.69 to 1.11], H3N2 (pooled RR 0.94 95% CI 0.85 to 1.04) 
or B strain (pooled RR 1.15, 95% CI 0.63 to 2.10). 
 
TNFi and influenza vaccination response 
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In total, 803 subjects from 7 studies were pooled in the meta-analysis examining 
TNFi impact on influenza vaccine immunogenicity (304 RA patients, 499 controls) (11-
17). Three studies exclusively examined the influence of TNFi exposure on pH1N1 
influenza response, these results were combined with seasonal influenza H1N1 
responses (15-17). TNFi exposure was not associated with reduced SP responses to 
H1N1 (pooled RR 0.86, 95% CI 0.72 to 1.04), H3N2 (pooled RR 0.98, 95% CI 0.74 to 
1.31) or B strain (pooled RR 1.38, 95% CI 0.70 to 2.72). 
RTX and influenza vaccine response 
 
Two studies have described reduced seasonal influenza vaccine responses 
in RTX treated patients compared to nbDMARD treated patients and HC (18, 19). 
Arad et al. (18) reported that a longer interval between RTX administration and 
influenza vaccination was associated with an improved Ab response in contrast to 
Oren et al. (19) who found no such relationship. 
 
ABA and influenza vaccine response 
 
Ribeiro et al. (20) reported a significantly poorer humoral response to pH1N1 
vaccination in ABA treated patients compared to age matched MTX treated 
patients and HC. Alten et al. described preserved influenza vaccine responses in 
296 ABA exposed patients pooling the results from 2 multi-centre, open-label sub-
studies (21). In total, 49.5% of patients achieved an appropriate post-vaccine 
humoral response. Despite vaccine responses not being compared against a 
comparator group, the authors felt the vaccine responses were preserved. 
 
TOC and influenza vaccine response 
 
Iwamoto et al. (15) reported appropriate humoral responses to pH1N1 
vaccination in TOC treated patients compared to HC. However, combination 
MTX+TOC compared to TOC monotherapy has been associated with a blunted 
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vaccine response in subjects receiving pH1N1 vaccination (22). Tsuru et al. (23) 
reported preserved SP rates for all 3 strains of seasonal influenza vaccine in TOC 
exposed compared to TNFi/nbDMARD treated patients. 
 
TOF and influenza vaccine responses 
 
The data on influenza vaccine response and TOF exposure are limited. 
Winthrop et al. reported 2 studies investigating humoral responses to trivalent 
influenza vaccine (24). In both studies, humoral response was considered as a 4 
fold increase in at least 2 of 3 influenza antigens, assessed 5 weeks post 
vaccination. The first study was undertaken in TOF naïve patients randomized 1:1 
to TOF 10mg BD or placebo, stratified by MTX exposure. Combination TOF+MTX 
therapy was associated with poorer influenza humoral response compared to 
placebo, TOF and MTX monotherapy. In the second study, the effect of temporary 
withdrawal of TOF compared to continuous therapy was investigated; temporary 
withdrawal of TOF (1 week pre and post vaccination) had no significant impact on 
humoral vaccine responses. 
 
Pneumococcal vaccination 
 
MTX and pneumococcal vaccination response 
 
Two studies reporting on 254 subjects (122 RA patients, 132 healthy 
controls) examining MTX exposure and 6B and 23F pneumococcal serotype 
responses were included in the meta-analysis (25, 26). From the limited data for 
the two serotype studies, MTX exposure was associated with a reduced vaccine 
response compared to HC (pooled RR 0.42, 95% CI 0.28 to 0.63). 
 
TNFi and pneumococcal vaccination response 
 
Two studies reporting on 273 subjects (141 RA patients, 132 healthy controls) 
assessing 6B and 23F pneumococcal serotype responses with TNFi exposure (25, 
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26) were included in the meta-analysis. From the limited data, TNFi exposure had 
no significant negative impact on vaccine response compared to HC, (pooled RR 
0.98, 95% CI 0.58 to 1.67). 
 
RTX and pneumococcal vaccine response 
 
Comparing RA patients treated with RTX+MTX (n = 65) with MTX 
monotherapy (n = 28), Bingham et al. (27) reported that RTX exposed patients had 
a reduced response to vaccination for each of the 12 PPV23 serotypes tested. The 
proportions of RTX treated patients with a positive vaccine response (to at least 1, 
2, 3, 4, 5, and 6 serotypes) was also decreased compared to MTX monotherapy. 
 
ABA and pneumococcal vaccine response 
 
The data on ABA exposure and humoral vaccine response are conflicting. 
Migita et al. (28) found significantly decreased Ab response rates for 6B and 
combined 6B/23F SR rates in ABA exposed patients compared to MTX and RA 
control groups. In contrast, Alten et al. (21) described preserved SP response to 
PPV23 vaccination with 55.4% of ABA exposed patients achieving adequate SP 
response to PPV23 vaccination. 
 
TOC and pneumococcal vaccine response 
 
TOC monotherapy is not associated with impaired PPV23 vaccine response 
however combination with MTX has been reported to blunt 6B and combined 
6B/23F serotype responses (23, 29, 30). 
 
TOF and pneumococcal vaccine response 
 
The data on TOF exposure and pneumococcal vaccine responses are limited; 
the results of two studies investigating pneumococcal responses in the context of TOF 
exposure were reported by Winthrop et al. (24). Combination of TOF+MTX was 
associated with reduced humoral response to PPV23 vaccine compared to placebo, 
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TOF or MTX monotherapy. Temporary withdrawal of TOF (1 week pre- and post 
PPV23 vaccination) had little effect on humoral vaccine response compared to 
continuous therapy. 
 
 
DISCUSSION 
 
Our meta-analysis found no detrimental effect of MTX therapy on influenza 
vaccination, but a diminished response to pneumococcal vaccination. There was 
no observation of an adverse humoral response to influenza or pneumococcal 
vaccination with TNFi exposure. 
 
Meta-analysis of pneumococcal vaccination responses with 
immunosuppression exposure was challenging due to the significant heterogeneity 
in reporting vaccine response; we only considered responses to 6B and 23F 
serotypes. Despite not being the most prevalent serotypes, bacterial pneumonia 
associated with 6B and 23F have a high mortality risk (31). We accept that vaccine 
response may differ across individual pneumococcal vaccine serotypes. Despite 
achieving a satisfactory response to one serotype, it is not appropriate to assume 
that vaccine responses for other serotypes will be equal. Vaccine efficacy was 
defined as achievement of post-vaccination SP Ab titres, however subjects could 
achieve SP without SR or SC. SP doesn’t provide information on vaccine efficacy 
and we acknowledge alternative methods of reporting vaccine immunogenicity and 
efficacy, e.g. OI or GMT rises. 
 
Vaccine responses for PCV-7 and PPV23 responses were pooled. PCV-7 
however is no longer part of the routine U.K vaccine schedule and was replaced by 
PCV-13. Both PCV-7 and PCV-13 include 6B and 23F serotypes. Although 
comparing a conjugated and polysaccharide vaccination may not be appropriate 
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when considering long term vaccine responses, comparison of vaccine 
immunogenicity at 3 to 6 weeks post vaccination is similar (32). 
 
Although it was not possible to undertake meta-analysis of the impact of RTX on 
humoral responses to influenza and pneumococcal vaccination, there are consistent 
reports in the literature of poorer serological responses to immunisation (19, 27, 33-
35). The timing of RTX has also been an important consideration in the assessment of 
vaccine immunogenicity; a greater interval between RTX administration and 
vaccination has been associated with an improved vaccine response (18). There were 
limited data to perform meta-analysis on TOC exposure on vaccine responses 
compared to healthy controls, although review of the literature suggests there no 
significant effect on PPV or influenza vaccine immunogenicity (22, 29). Comparatively, 
ABA has been reported to impair the responses to pH1N1 and PPV23 response (20, 
28). TOF in combination with MTX is associated with reduced influenza and 
pneumococcal vaccine responses. Temporary withdrawal of TOF no significant effect 
on influenza or PPV vaccine immunogenicity. 
 
EULAR guidelines recommend vaccination against influenza and pneumococcal 
disease should be undertaken prior to commencement of TNFi or nbDMARD therapy, 
we accept that in practice this is challenging and may be unrealistic. EULAR guidance 
(3) also advises vaccination should be undertaken in a period of disease stability 
however in U.K. practice, biologic drugs (often a trigger to administer vaccinations) are 
only considered in patients with persistent high disease activity states (DAS28 >5.1). 
There is limited evidence that vaccine responses are attenuated in RA in patients with 
high disease activity states. A key clinical decision is determining the best time to 
vaccination, either before immunosuppressive therapy or in a period of disease 
stability. Live vaccines are currently contraindicated in the 
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setting of immunosuppression. If a live vaccine is indicated, vaccination should be 
administered 2 to 4 weeks prior to immunosuppression, or at least 3 months after 
stopping nbDMARDs. The Centers for Disease Control and Prevention have 
provided guidance on the safety of the shingles vaccine in the context of 
immunosuppression; it is safe to administer the shingles vaccine in patients on 
nbDMARDs including Azathioprine and MTX but it avoided in patients on biologics 
and high-dose prednisolone (>20 mg per day) (36). 
 
Only 2 studies included in the meta-analyses reported specifically on the 
effect of vaccination on disease activity however several confirm no evidence of a 
detrimental effect on parameters of disease activity post vaccination (13, 17-19, 33, 
34, 37-40). 
 
To our knowledge, there has been 1 previous meta-analysis assessing the 
influence of anti-rheumatic drug therapies on influenza and pneumococcal vaccine 
responses (41). Of note, there was an alternative methodological approach to 
analysis and probable access to unpublished data. In Hua’s meta-analysis, the 
definitions and characteristics of treatment exposed and control groups differed, for 
example when assessing the influence of MTX on pneumococcal vaccine 
response, the experimental group compared MTX + TNFi exposed patients to TNFi 
monotherapy rather than HC. 
 
We recognise that biologics are co-prescribed with nbDMARDs including MTX 
in routine clinical practice. However, by comparing drug therapies with HC groups in 
our analysis, we felt it would allow better assessment of the impact of drug therapy on 
vaccine immunogenicity, albeit to the detriment of potential number of studies and 
subjects that could be included in meta-analysis. Additionally, we have considered 
newer anti-rheumatic therapies including ABA, TOC and TOF. Our assessment of 
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MTX exposure negatively impacting pneumococcal vaccine response is congruent 
with Hua and colleagues, although we did not observe a negative influence of MTX 
on influenza vaccination. 
 
The NOS was used to assess the risk of bias and grade the quality of 
included studies. All studies were of ‘satisfactory’ or ‘good’ quality however, there 
are sources of bias in our meta-analysis that we acknowledge. 
 
Our review was potentially subject to outcome reporting bias. We only 
included studies reporting on post-vaccine Ab titres (rather than OI or GMT 
responses) as it was the most commonly reported method of assessing vaccine 
response. Literature review identified several studies that could not be included 
due to the heterogeneity in study design or differing methods of reporting vaccine 
efficacy, particularly those reporting on pneumococcal vaccine immunogenicity. 
Several studies reported on Ab response rates, GMT rises or OI without providing 
numerical data on response rates for SP, SR or SC. However, the conclusions 
drawn from each study agreed with our findings and provided further evidence that 
TNFi do not significantly diminish the response to pneumococcal or influenza 
vaccines (33, 38, 39, 42-46). 
 
We included 2 studies from a single centre analysing vaccine responses of 2 
pneumococcal serotypes (6B and 23F), thus the generalizability of our conclusions 
is limited. A strength is that both studies were methodologically similar and good 
quality with low risk of bias. There was a relative paucity of data examining newer 
biologic agents including RTX, ABA, TOC and TOF compared to TNFi drugs, this 
may be a result of publication bias. 
 
Adjustment for confounding factors including age and smoking status or 
significant comorbidity which could impact on vaccine immunogenicity was not 
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possible. Control groups were not necessarily age matched to the RA cohorts. 
Older subjects are have a higher risk of serious infection and attenuated vaccine 
responses to vaccination, a consequence of immunosenescence (44, 47). Smoking 
may reduce pneumococcal vaccine responses in RA patients treated with MTX 
(48), however this was poorly reported in studies included. Most studies examined 
established RA cohorts (evidenced by RA disease duration prior to vaccination). It 
is uncertain whether longer disease duration (and potentially historically more 
immunosuppressive exposures) impacts upon vaccine response; this was outside 
the scope of this study. 
 
Seasonal and pandemic influenza vaccination utilise strains that vary each 
season depending on the most virulent predicted strains. Although vaccine 
responses were broadly categorised by A or B strain responses for the meta-
analysis, there may have been variation in the immunogenicity of each vaccine 
between studies, this was not possible to correct for. 
 
Co-prescription of MTX with a biologic is recommended to maximise efficacy 
and reduce drug immunogenicity. We aimed to compare TNFi monotherapy to a 
HC group to prevent aberrancies due to MTX exposure. Concerning influenza 
vaccine responses with TNFi exposure, 3 studies included patients taking TNFi 
with concomitant MTX (12, 15, 16). Excluding these studies increased the 
heterogeneity but not RR interpretation. Three of the 4 other studies included in the 
meta-analysis did not explicitly comment if TNFi exposed patients were taking 
concurrent MTX (13, 14, 17). Additionally, the studies included different TNFi 
drugs. We assumed that TNFi exposure had similar class effects irrespective of 
whether they were a monoclonal antibody or fusion receptor protein. 
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Our meta-analysis and systematic review suggests that MTX exposure 
diminishes humoral responses to pneumococcal but not influenza vaccination. TNFi 
therapy does not negatively impact influenza or pneumococcal vaccine responses. 
Immunosuppression should not preclude vaccination against immune preventable 
disease. Vaccination is safe and well tolerated and should be encouraged as part of 
routine clinical care. Increasing the awareness and uptake of vaccinations in RA 
patients will require collaborative approaches between primary and secondary care. 
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Figure Legends 
 
 
 
Figure 1: Flow chart of studies included in the systematic review and meta-analysis 
 
 
 
 
Figure 2: Forest plots for the risk ratios of response rates for influenza vaccine 
serotypes between rheumatoid arthritis patients receiving anti-tumour necrosis 
factor drugs or methotrexate and healthy controls 
 
Legend: 95% CI = 95% Confidence Interval; M-H = Mantel-Haenszel; MTX = 
Methotrexate; TNFi = Tumour Necrosis Factor inhibitor Drug 
 
 
 
Figure 3: Forest plot for the risk ratios of response rates for pneumococcal vaccine 
(combined 6B and 23F serotype responses) between rheumatoid arthritis patients 
receiving methotrexate or anti-tumour necrosis factor drugs and healthy controls 
Legend: 95% CI = 95% Confidence Interval; M-H = Mantel-Haenszel; MTX = 
Methotrexate; TNFi = Tumour Necrosis Factor inhibitor Drug 
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Table 1: Characteristics of the studies examining influenza vaccine immunogenicity included in the meta-analysis 
 
Author, Year Study Number Vaccine Outcome Age, % Disease DAS28 HAQ Seroconversion Seroprotection NOS 
 
(ref)   design of    years Women duration, score score % (95% CI) % (95% CI) score 
 
    Subjects    (SD)  years (SD)     
 
    (n)      (SD)      
 
                
 
MTX                
 
                
 
Franca et al. Prospective RA MTX Pandemic SP: HI  RA 46.5 RA 67, 15.6 (10.4) - - RA 56.0 (36.5, RA 56.0 (36.5 - 7 
 
2012 (16)   (25), HC Influenza >1:40  (10.6), HC 79    75.5), HC 74.3 75.5), HC 78.6  
 
   cohort 
(117) A/H1N1/2009 SR: >4- HC  44.3 
    
(66.4, 82.3) (71.2 - 86.1) 
 
 
         
 
   study   fold  (12.4)        
 
      increase         
 
      from          
 
      baseline         
 
      after 3         
 
      weeks          
 
                
 
Iwamoto et al. Prospective RA MTX Pandemic SP: HI  RA RA 98, - - - RA 58.5 (44.1 – RA 60.4 (46 – 5 
 
2012 (15) §  cohort (41), HC Influenza >1:40  median HC -    71.9) ** 73.6) **, HC  
 
   study (14) A1/H1N1/2009 SR: >4- 67 (range     HC 64.3 71.4  
 
      fold  29-90)        
 
      increase         
 
      from          
 
      baseline         
 
      after 3         
 
                
 
Page 26 of 55 
 
 
 
 
 
 
 
      weeks             
                
Kapetanovic et Prospective RA MTX Influenza SP: HI  RA 61.3 RA 68, Median Pre  - - RA H1N1 89%, 6 
al. 2007 (11)  cohort (37), HC trivalent >1:40  (20.8- HC 74 7.0 (min Vaccine    H3N2 76%, B  
   study (18) subunit SR: >4- 81.4)   0.9– max DAS28,    95%, HC H1N1  
     vaccine, fold  HC 30.3  46.9  low 53,   78%, H3N2  
     H1N1/H3N2/B increase (19.2-    med 35,   72%, B 67%  
      from  60.3)     high12      
      baseline            
      after 4-6            
      weeks             
                 
Kobie et al. Prospective RA MTX Influenza SP: HI  RA 58.4 RA 77, >3years -  0.71 - RA H1N1 88%, 6 
2011 (12)  cohort (70), HC trivalent >1:40  (12.2) HC 63 60%, <1   (0.00-  H3N2 94%, B  
   study (97) subunit SR: >4- HC 39.8  year 17%   2.22)  97%, HC H1N1  
     vaccine fold  (13.6)        100%, H3N2  
     H1N1/H3N2/B increase          100%, B 100%  
      from             
      baseline            
      after 4            
      weeks             
                  
Ribeiro et al. Prospective RA MTX Influenza SP: HI  RA 55.8 RA 87, 16.7 (10.4) Pre  - RA 46.3 (39.6 - RA 53.2(46.6 - 7 
2011 (17)  cohort (215), HC A/H1N1/2009 >1:40  (11.5) HC -   Vaccine   53.0) 59.9), HC 82.9  
   study (234)  SR: >4-       3.66   HC: 76.9 (71.0 - (77.5 - 87.5)  
      fold       (1.35),   82.2)   
      increase      Post      
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      from     Vaccine     
      baseline    3.49 (1.36)     
      after 3     No     
      weeks     significant     
           change     
                
TNFI                
                
Franca et al. Prospective RA (41) Pandemic SP: HI  RA RA 60, 18.4 (10.1) - - RA 65.9 (51.3, RA 65.9 (51.3- 7 
2012 (16)  cohort (IFX/ADA Influenza >1:40  45.1 HC 79    80.4) 80.4), HC 78.6  
   study 30, 11 A/H1N1/2009 SR: >4- (11.8)     HC 74.3 (66.4, (71.2- 86.1)  
    ETA), HC  fold  HC 44.3     82.3)   
    (117  increase (12.4)        
      from          
      baseline         
      after 3         
      weeks          
                
Iwamoto et al. Prospective RA (28) Pandemic SP: HI  RA RA 100, - - - RA 38.9 (23.1 – RA 47.2 (30.4 – 5 
2012 (15) §  cohort IFX 3, ETA Influenza >1:40  median HC -    56.5) * 64.5) *, HC  
   study 18, ADA A1/H1N1/2009 SR: >4- 64.5     HC 64.3 71.4  
    7), HC  fold  (range        
    (14)  increase 29-78)        
      from          
      baseline         
      after 3         
      weeks          
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Kapetanovic et Prospective RA TNFi Influenza SP: HI  RA RA 76, Median Pre  - - RA H1N1 58%, 6 
al. 2007 (11)  cohort (62) (IFX trivalent >1:40  median HC 74 20.8 (min Vaccine   H3N2 74%, B  
   study 27, ETA subunit SR: >4- 53.7  1.5- max DAS28,   87%, HC H1N1  
    35), HC  H1N1/H3N2/B fold  (15.1-  55.9)  low 49%,   78%, H3N2  
    (18)   increase 85.3)    medium   72%, B 67%  
       from  HC  30.3    41%, high     
       baseline (19.2-    10%      
       after 4-6 60.3)          
       weeks            
                  
Kobie et al. Prospective RA: TNF Influenza SP: HI  RA 55.4 RA 82, >3 years -  0.71 - RA H1N1 97% 6 
2011 (12)  cohort (61)  trivalent >1:40  (12.3) HC 63 93%,    (0.00-  H3N2 94% B  
   study (ETA 35, subunit     <1year 5%   2.22)  97%, HC H1N1  
    IFX 17, H1N1/H3N2/B SR: >4-         100%, H3N2  
    ADA 9),  fold          100%, B 100%  
    HC (97)   increase           
       from            
       baseline           
       after 4           
       weeks            
                  
Kubota et al. Prospective RA TNFi Influenza SP: HI  RA 55.7 - -  -  - - RA H1N1 6 
2007 (14)  cohort (27)  trivalent >1:40  (12.6)        44.4%, H3N2  
   study (ETA  subunit SR: >4- HC 55.9        44.4%, B  
    11/IFX 16) H1N1/H3N2/B fold  (9.82)        29.6%, HC  
       increase         H1N1 17.3%,  
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    HC (52)  from         H3N2 25%, B  
      baseline        9.6%  
      after 4-          
      6weeks           
                
Ribeiro et al. Prospective RA: TNF Pandemic SP: HI  RA 55.8 RA 87, 16.7 (10.4) Pre - RA: 51.0(45.0 to RA 67.4 (53.7- 7 
2011(17)   cohort (47) Influenza >1:40  (11.5) HC -  Vaccine:  57.0)  81.1), HC 82.9  
   study (20 IFX, A/H1N1/2009 SR: >4-    3.66 (1.35)  HC: 76.9(71.0 to (77.5-87.5)  
    16 ADA,  fold     Post  82.2)    
    11 ETA),  increase    Vaccine:      
    HC (234)  from     3.49 (1.36)      
      baseline    No      
      after 3    significant      
      weeks     change      
                 
Salemi et al Prospective RA TNFi Influenza SP: HI  RA 53 (3) RA 82, - 2.47 (0.2), - RA TNF  RA H1N1 68%, 5 
2010 (13)  cohort (28) trivalent >1:40   HC -  no  H1N1  H3N2 75%, B  
   study (n = subunit SR: >4-    significant  45%/H3N2  50%, HC H1N1  
    unknown H1N1/H3N2/B fold     change  at  35%/B 15% 90%, H3N2  
    IFX, ADA,  increase    30 days  HC: H1N1 80%, B 40%  
    ETA), HC  from       50%/H3N2    
    (20)  baseline      60%/B 20%   
      after 30          
      days           
                 
 
 
Legend: § additional data supplied on request by the author; RA = Rheumatoid arthritis; HC = Healthy Control; TNFi = Tumour Necrosis Factor inhibitor drug; IFX = Infliximab; ADA = Adalimumab; 
ETA = Etanercept; MTX = Methotrexate; HI = haemagglutination inhibition assay; SP = Seroprotection; SR = Seroresponse; * DAS28 = Disease Activity Score in 28 joints, scores pre vaccination are 
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quoted unless stated otherwise; HAQ = Health Assessment Questionnaire; 95% CI = 95% Confidence Interval; - = data not provided; Disease duration = mean disease duration unless otherwise 
stated; ** includes RA patients on non-biological DMARDs including non-MTX users; NOS = Newcastle Ottowa Score 
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Table 2: Characteristics of the studies examining pneumococcal vaccine immunogenicity included in the meta-analysis 
 
Author, Study Number of Vaccine Outcome Age, years % Women Disease DAS28 HAQ SC % SP % NOS score 
Year (ref) Design Subjects Intervention  (SD) (SD) duration score (SD)  (95% CI) (95% CI)  
  (n)     years (SD)      
             
MTX             
             
Kapetanovic Prospective RA MTX PPV-23 2-fold RA 61.3 RA:68 Median 7.0 Pre - - RA 13.5 5 
et al. 2006 cohort (37), HC  increase in (20.8-81.4) HC: 74 (minimum Vaccine   HC 38.2  
(25) study (47)  post- HC 30.3  0.9 - DAS28, low     
    vaccination (19.2-60.3)  maximum 53%     
    titres for 6B   46.9) medium     
    and 23F    35%, high     
    serotypes,    12%     
    4-6 weeks         
    post         
    vaccination         
             
Kapetanovic Prospective RA MTX PCV-7 2-fold RA 61.5 RA 78.8 RA 11.4 RA 0.7 (0.6) - RA 21.2 6 
et al. 2011 cohort (85), HC  increase in (14)  (10) 3.7 (1.2)   HC 47.7  
(26) study (86)  post- HC 51.6 HC: 45 HC 12.7      
    vaccination (12)  (12)      
    titres for 6B         
    and 23F         
    serotypes,         
    4-6 weeks         
    post         
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vaccination 
 
TNFi 
 
Kapetanovic Prospective RA TNFi PPV-23 2-fold RA median RA: 76 Median Pre - - RA 50 5 
et al. 2006 cohort (62)  increase in 53.7 (15.1- HC: 74 20.8 (1.5 - Vaccine   HC 38.2  
(25) study (IFX  post- 85.3), HC  55.9) DAS28, low     
  27/ETA 35)  vaccination median   49%,     
  HC (47)  titres for 6B 30.3 (19.2-   medium     
    and 23F 60.3)   41%, high     
    serotypes,    10%     
    4-6 weeks         
    post         
    vaccination         
             
Kapetanovic Prospective RA TNFi PCV-7 2-fold RA 59.8 RA TNF: 87 RA 20.6 RA 3.9 1.2 (0.7) - RA 36.7 6 
et al. 2011 cohort (79)  increase in (14), HC HC: 45 (11) (1.1)   HC 47.7  
(26) study (TNFi not  post- 51.6 (12)  HC 12.7      
  specified)  vaccination   (12)      
  HC (85)  titres for 6B         
    and 23F         
    serotypes,         
    4-6 weeks         
    post         
    vaccination         
             
 
Legend: RA = Rheumatoid arthritis; HC = Healthy Control; TNFi = Tumour Necrosis Factor inhibitor drug; IFX = Infliximab; ADA = Adalimumab; ETA = Etanercept; MTX = Methotrexate; HI = 
haemagglutination inhibition assay; * DAS28 = Disease Activity Score in 28 joints, scores pre-vaccination are quoted unless stated otherwise; HAQ = Health Assessment Questionnaire; 95% CI = 
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95% Confidence Interval; - = data not provided; PPV23: Pneumococcal polysaccharide vaccine; PCV-7: Conjugate pneumococcal vaccine; Disease duration = mean disease duration unless 
otherwise stated; Age = mean age unless otherwise stated, NOS score = Newcastle Ottowa Score 
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Figure 1: Flow chart of studies included 
in the systematic review and meta-
analysis 
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Figure 2: Forest plots for the risk ratios of response rates for influenza vaccine serotypes between 
rheumatoid arthritis patients receiving anti-tumour necrosis factor drugs or methotrexate and 
healthy controls 
 
 
 
 
 
 
 
 
(a) Treatment with MTX and H1N1 strain responses  (including pandemic and seasonal  H1N1 pooled)  
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(b) Treatment with TNFi and H1N1 strain responses  (including pandemic and seasonal  H1N1 pooled)  
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(c) Treatment with MTX and H3N2 strain responses  
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(d) Treatment with TNFi and H3N2 strain responses  
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(e) Treatment with MTX and B strain responses  
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(f) Treatment with TNFi and B strain responses  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend: 95% CI = 95% Confidence Interval; M-H = Mantel-Haenszel; MTX = Methotrexate; TNFi 
= Tumour Necrosis Factor inhibitor Drug 
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Figure 3: Forest plot for the risk ratios of response rates for pneumococcal vaccine (combined 6B 
and 23F serotype responses) between rheumatoid arthritis patients receiving methotrexate or anti-
tumour necrosis factor drugs and healthy controls 
 
 
 
 
 
 
 
 
 
 
(a) Treatment with MTX and pneumococcal 6B/23F serotype responses  
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(b) Treatment with TNFi and pneumococcal 6B/23F serotype responses  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend: 95% CI = 95% Confidence Interval; M-H = Mantel-Haenszel; MTX = Methotrexate; TNFi = 
Tumour Necrosis Factor inhibitor Drug 
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Supplementary Table 1: Quality assessment of studies using the Newcastle Ottowa Score 
 
  Selection  Comparability  Outcome        
 
             
 
 
Representativeness Selection of  Demonstration that   Was follow-up Adequacy Total  Comment    
the non- Ascertainment outcome of interest Comparability Assessment long enough       
Study of the exposed of follow up NOS       
exposed of exposure was not present at of cohorts of outcome for outcomes        
cohort of cohorts score        
cohort  start of study   to occur?                   
 
          RA and control 
 
Franca 2012 
         cohorts not  aged 
 
1 1 1 1 0 1 1 1 7 matched.  Control  
(16)            population   from              
 
          hospital population. 
 
            
          Method of recruitment 
 
          of  RA  or control 
 
          cohorts   not 
 
          discussed.    
 
Iwamoto 
1 0 0 0 0 1 1 1 5 Demographic data for  
2012 (15) comparability  of            
 
          cohorts   not 
 
          presented. Previous 
 
          vaccination status not 
 
          documented.   
 
              
          RA and control 
 
          cohorts were not 
 
          aged  matched. 
 
Kapetanovic 
         Controls   were 
 
1 0 1 0 0 1 1 1 5 selected from healthy  
2006 (25)           hospital controls.            
 
          Previous vaccination 
 
          status   not 
 
          documented.   
 
             
 
          RA and control 
 
          cohorts not  aged 
 
          matched. Controls 
 
Kapetanovic 
1 0 1 0 1 1 1 1 6 were selected from  
2007 (11) healthy  hospital            
 
          controls. Previous 
 
          vaccination status not 
 
          documented.   
 
Kapetanovic          
RA and control 
 
1 0 1 1 0 1 1 1 6 cohorts not  aged  
2011 (26)            
matched.                  
 
          RA and control 
 
Kobie 2011 
1 0 1 1 0 1 1 1 6 
cohorts not  aged 
 
(12) matched.                 
 
               
 
Page 44 of 55 
 
 
 
 
 
 
 
Kubota 2007          No information of how  
1 0 0 1 1 1 1 1 6 control  cohort were  
(14)           recruited.                
 
Ribeiro 2011          
RA and control 
 
1 1 1 1 0 1 1 1 7 cohorts not aged  
(17)           
matched.                
 
Salemi 2009          No data presented  
1 0 0 1 0 1 1 1 5 comparing ages  of  
(13)           
two cohorts.              
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COHORT STUDIES 
 
Selection (4 points in total) 
 
Representativeness of the exposed cohort (1 point) 
 
Yes if: 
 
 rheumatoid arthritis (RA) diagnosis confirmed by American College of 
Rheumatology (ACR) 1987/2010 criteria.  
 details on selection process of the RA cohort, e.g. randomly selected from a 
hospital clinic, or invited via postal-invitation to participate in the study 
 
No if: 
 RA patients do not fulfil ACR RA diagnostic criteria 
 details on the method of recruitment of RA patients not presented 
 
Selection of the non-exposed cohort (1 point) 
 
Yes if: 
 
 RA patients serving as healthy cohorts were stated to not have 
any immunosuppressive exposure prior to vaccination 
 the healthy control cohort were randomly selected from the local population 
 
No if: 
 the control cohort were drawn from a hospital workers only 
 the control drawn from a different source and not from the same community 
 there was no description of the derivation of the non-exposed cohort 
 
Ascertainment of exposure (1 point) 
 
Yes if: 
 
 it was documented that no recent vaccination against influenza (within the 
same vaccination season) and/or pneumococcal vaccine (within 5 years) 
had been performed  
 details were from a secure record (e.g. medical records) 
 
No if: 
 
 there was no description of pre-vaccination antibody titres or no evidence 
of exclusion criteria including previous vaccination history 
 
Demonstration that outcome of interest was not present at start of study (1 point) 
 
Yes if: 
 
 pre-vaccine titres were checked pre-immunisation and details provided on 
to calculate number/proportion of patients who achieved seroprotection, 
seroconversion or seroresponse 
 
No if 
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 there was no history of vaccination within 12 months for influenza 
vaccination or 5 years for pneumococcal vaccination 
 
Comparability (2 points) 
 
Yes if: 
 RA and control cohorts were age matched 
 RA and control cohorts were age and sex matched 
 The RA population serving as a control cohort, matched for disease duration 
 
No if: 
 Cohorts not age matched 
 
Outcome (3 points) 
 
Assessment of outcome (1 point) 
 
Yes if: 
 
 The percentages of achieving seroprotection or seroconversion 
calculable from data presented 
 Blinded analysis of post-vaccination titres 
 
No if: 
 No data presented for post vaccination titres 
 
Was follow-up long enough for outcomes to occur (1 point) 
 
Yes if: 
 
 3-6 week follow up period for post-vaccination titres to assess 
seroprotection or seroconversion 
No if: 
 
 Follow up period outside set time frame 
Adequacy of follow up of cohorts (1 point) 
 
Yes if: 
 Complete follow up - all subjects accounted for or >80% subject follow up rate 
 
No if: 
 Follow up rates unable to be calculated or data not presented 
 
 
Interpretation of Newcastle Ottowa Scale score: 
0 – 3 = poor quality study 
4 – 6 = satisfactory quality study 
7 – 9 = high quality study 
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Supplementary Table 2: Studies examining pneumococcal vaccine responses with different anti-rheumatic drug exposures 
 
Author, Subjects (n) Vaccine Outcome Mean Age, Female n (%) Disease DAS28 score (SD) HAQ score Vaccine response Comments   
Year    years (SD)  duration,  (SD)       
[Reference]      years (SD)         
             
Kapetanovic RA (149, 62 PPV23 ≥ 2-fold or higher Median age: TNFi (76) TNFi 20.8 % of patients with - % of patients with MTX associated with 
et al. 2006 TNFi  increase in 6b and TNFi TNFi + TNFi + MTX Low/Intermediate/High  adequate vaccine a reduced response to 
(25) monotherapy,  23f serotype Ab monotherapy MTX (70) 10.8 DAS28 at time of  response: PPV23 vaccination, 
 50 TNFi +  concentration, 4 to 6- 53.7 MTX (68) MTX 7.0 vaccination:  TNFi 50%, no effect of TNFi on 
 MTX, 37 MTX  weeks post TNF+MTX HC (74) HC - TNFi: 49/41/10  TNFi + MTX 32%, vaccine response  
 monotherapy)  vaccination 52.8   TNF+MTX: 50/44/6  MTX 13.5%,      
 HC (47)   MTX   MTX: 53/35/12  HC 38.2%      
    monotherapy           
    61.3           
    HC 30.3           
              
Visvanathan RA (70, PPV23 ≥ 2-fold increase at Median age: IFX 3mg/kg: - - - >80% of patients in No impact of MTX 
et al. 2007 20 IFX  least 6 vaccine IFX 3mg/kg: (65)    each group exposure on vaccine 
(44) 3mg/kg +  serotypes compared 52 IFX 6mg/kg:    responded to 1≥ responses    
 MTX, 36 IFX  to pre-vaccine levels IFX 6mg/kg (66.7)    serotypes, 20-25%      
 6mg/kg +   50 Placebo    responded to 6≥      
 MTX, 14   Placebo 50 (78.6)    different serotypes      
 Placebo +              
 MTX)              
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Kaine et al. RA (218, 109 PPV23 ≥ 2-fold titre increase 51.7 ± 11.66 Placebo 82 - - - % of patients No  impact  of  TNFi 
2007 (42) Placebo ±  in ≥ 3 of 5 vaccine  (75.2),    achieving a ≥ 2-fold exposure on vaccine 
 MTX, 109  serotypes and  ADA 84    increase in ≥ 3 of 5 responses   
 ADA ± MTX)  protective Ab titres  (84.8),    pneumococcal Ab    
   ≥1.6 mcg/ml, 4-weeks  Overall 166    titres: ADA 37.4%,    
   post vaccination.  (79.8)    Placebo 40.4%. % of    
   Serotypes 9V, 14,      patients achieving    
   18C, 19F, and 23F      protective Ab titres    
         >1.6mcg/ml in ≥ 3 of    
         5 antigens) 4 weeks    
         post vaccination:    
         ADA 85.9%, Placebo    
         81.7%    
             
Bingham et RA (93, PPV23 ≥2-fold increase or an RTX + MTX RTX + MTX - RTX +MTX 6.2 (1.1) - Decreased Reduced  vaccine 
al. 2010 RTX+MTX  increase of 1 mcg/ml 49.7 (9.6) 51 (75), MTX  MTX -  responses to PPV23 response in RTX 
(27) 65, MTX 28)  from pre-vaccination MTX 49.7 25 (78)    RTX+MTX 57% of exposed  patients 
   level. 12 (10.5)     subjects had a 2-fold compared to MTX 
   pneumococcal      rise in Ab titre    
   serotype responses      response to >1    
   assessed      serotype, compared    
         with 82% of MTX    
         monotherapy    
         patients. Lower    
         proportions of    
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         patients responding    
         to each serotype in    
         RTX+MTX group    
         compared to MTX    
         monotherapy    
             
Kapetanovic RA (253, PCV-7 ARR ≥ 2, 4 to 6- MTX MTX: 67 MTX 11.4 MTX 3.7 (1.2) MTX Number (%) of MTX associated with 
et al. 2011 MTX 85,  weeks post- 61.5 (14) (78.8) (10) TNFi + MTX 3.4 (1.2) 0.7 (0.6) subjects achieving ≥ a reduced response to 
(32) TNF+MTX  vaccination, TNFi + MTX TNFi + MTX TNFi + MTX TNFi 3.9 (1.1) TNFi + 2-fold increase in PCV-7, no effect of 
 89, TNF 79)  serotypes 6b and 23f 60.1 (10) 69 (77.5) 16.2 (12) SpA/HC 3.0 (1.1) MTX 0.9 pre-vaccination Ab TNFi therapy on 
 SpA/HC (85)   TNFi 59.8 TNFi 69 TNFi 20.6  (0.7) levels vaccine response  
    (14) (87.3) (11)  TNFi 1.2 MTX 18 (21.2), TNFi    
    SpA/HC 51.6 SpA/HC 39 SpA/HC 12.7  (0.7) + MTX 14 (15.7),    
    (12) (45.3) (12)  SpA/HC TNFi 29 (36.7),    
        0.5 (0.5) SpA/HC 41 (47.7)    
            
Mori et al. RA (190, PPV23 ≥2-fold in IgG MTX 68.3, MTX 51 MTX 10.0, - - Fold increases 6b/23f Post-vaccination Ab 
2012 (29) MTX 62, TOC  concentrations or TOC + MTX (82.3), TOC + TOC + MTX   (SD) responses  may be 
 + MTX 54,  ≥10-fold or more 65.1, TOC MTX 50 9.1, TOC   MTX 1.5 (1.1-3.0)/ reduced  when TOC 
 TOC 50,  increase in 68.3, Control (92.6), TOC 12.5, Control   2.6 (1.4-4.1 combined with MTX. 
 Control 24)  opsonisation indices 69.2 43 (86), 11.3   TOC + MTX 1.6 (1.2-    
     Control 19    1.9)/ 2.9 (1.0-6.9),    
     (79.2)    TOC 2.8 (1.4-4.4)/    
         3.4 (1.5-6.8), Control    
         1.8 (1.3-3.7)/ 3.5    
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         (1.7-5.6)     
           
Kivitz et al. RA (207, PPV23 ≥ 2-fold increase in ≥ Placebo 52.7 Placebo Placebo 7.9 Placebo 5.5 (0.9), - Adequate response No significant effect of 
2014 (43) Placebo +/-  3 of 6 pneumococcal (11.1), CZP (76.3), CZP (8.4), CZP 7.4 CZP 5.5 (1.0)  in patients TNFi exposure on 
 MTX 110,  antigens at 6 weeks, 53.1 (11.8) (83.6) (8.1)   with/without vaccine response.  
 CZP+/- MTX  serotypes: 6b, 9v, 14,      protective titres at     
 107)  18c, 19f, 23f      baseline: Placebo     
         58.2%/62.5%, CZP     
         53.3%/54.5%     
           
Tsuru et al. RA (21, TOC) PPV23 ≥2-fold increase in Ab 54 17 (81) 9.0 - - 100% patients No comparator group 
2014 (23)   titres in at least 6 of      achieved adequate in study.   
   12 measured      sero-response     
   serotypes           
           
Bingham et RA (74, TOC PPV23 ≥2-foldincrease or an TOC + MTX TOC+MTX TOC+MTX - - Proportions of No significant effect of 
al, 2015 + MTX 50,  increase of 1 mcg/ml 51.1 (8.9), 41 (75.9), 13.2 (11.5),   responders to ≥6 of TOC exposure on 
(30) MTX 24)  from pre-vaccination MTX 51.4 MTX 22 MTX 8.4 (7.0)   12 anti- vaccine  response, 
   level, to ≥6/12 (9.5) (81.5)    pneumococcal however individual 
   serotypes      antibody serotypes: serotype responses 
         TOC + MTX 60%, may vary.   
         MTX 70.8%     
              
Page 51 of 55 
 
 
 
 
 
 
 
Migita et al. RA (111, RA PPV23 ≥2-fold increase in RA control RA control 23 RA control RA control 2.79 - Fold increase in GMT Reduced responses in 
2015 (28) control  IgG concentrations of 70.5 (10.8), (65.7), MTX 11.7 (12.5), (1.17), MTX 2.61  6b (95%CI)/23f (95% ABA and  MTX 
 35, MTX 55,  6b or 23f serotypes MTX 63.8 44 (80), ABA MTX 14.1 (0.98), ABA 2.48  CI) RA control 2.38 exposed  patients 
 ABA 21)   (11.5), ABA 17 (81) (10.9), ABA (1.31)  (1.41 - compared to RA 
    59.8 (12.0)  13.5 (11.2)   5.62)/3.36(1.85 to control group.   
         9.42), MTX     
         1.75(1.15-3.11)/     
         2.00(1.27 to 5.48),     
         ABA 1.41(0.87-3.09)/     
         2.45 (1.23-7.44)     
            
Alten et al. RA (125, 115 PPV23 ≥2-fold increase in 45.7 (13.8) 107 (85.6) - 5.0 (1.9) 1.4 (0.8) 83.9 % demonstrated No comparator group 
2016 (21) ABA + MTX,  post-vaccination titers      protective Ab levels in study.    
 10 ABA)  to ≥3 of 5 antigens      following PPV23     
   and      vaccination.     
   protective Ab levels           
   of ≥1.6 mcg/mL to ≥3           
   of 5 antigens.           
   Serotypes           
   measured 9V, 14,           
   18C, 19F, 23F           
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Winthrop et RA (200, PPV23 2-fold increase in RA (TOF RA (TOF - RA (TOF exposed) - TOF overall 46/102 TOF exposure, 
al. 2016 TOF + MTX  post-vaccination titers exposed) 53 exposed) 75  6.03 (1.05)  (45.1%) particularly  in 
(24) 57, TOF 45,  to ≥6 of 12 antigens, RA (placebo (73.5) RA  RA (placebo or MTX  demonstrated combination with MTX 
 MTX 55,  5-weeks post- or MTX (placebo or  monotherapy) 5.78  appropriate vaccine is associated with 
 placebo 43)  vaccination. monotherapy) MTX  (1.10)  response. In TOF reduced humoral 
   Serotypes measured 53 monotherapy)    non-exposed response  to PPV23 
   1,3,4,5,6B,7F,14,19A,  79 (80.6)    patients, response vaccination.   
   19F, 23F, 18C)      rate was higher Temporary withdrawal 
         67/98 (68.4%). of TOF has no benefit 
         Achievement of on vaccine response 
         appropriate PPV23 compared  to 
         vaccine response continuous therapy. 
         stratified by MTX use     
         at baseline: TOF +     
         MTX 18/57 (31.6%),     
         TOF monotherapy     
         28/45 (62.2%). MTX     
         monotherapy 34/55     
         (61.8%)     
         demonstrated     
         appropriate vaccine     
         response compared     
         to 33/43 (76.7%) in     
         the placebo group.     
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Legend: n: number, SD: standard deviation, DAS28: Disease Activity Score of 28 joints, HAQ: Health Assessment Questionnaire, RA: rheumatoid arthritis, HC: Healthy Controls, SpA: 
 
Spondyloarthropathy, MTX: methotrexate, TNFi: Tumour Necrosis Factor inhibitor drug, PPV23: pneumovax vaccine, PCV-7: 7 conjugate pneumococcal vaccine, PCV-13: 13 conjugate 
 
pneumococcal vaccine, Ab: antibody, ARR: antibody response ratio (i.e., ratio of post to pre-vaccination antibody levels), DMARD: Disease Modifying Anti-Rheumatic Drug, RTX: Rituximab, ABA: 
 
Abatacept, TOC: Tocilizumab, IFX: infliximab, CZP: Certolizumab pegol, ADA: Adalimumab, ETA: Etanercept, TOF: Tofacitinib 
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A Systematic Review and Meta-Analysis of Anti-Rheumatic Drugs and Vaccine 
 
Immunogenicity in Rheumatoid Arthritis 
 
Supplementary material – Literature Search Strategy 
 
Initial search undertaken 6
th
 October 2016, repeated 12
th
 October 2017 
 
Databases: 
 
1. EMBASE 1974 – 2017 Week 41 
 
2. Ovid MEDLINE ® Epub Ahead of Print, In-Process & Other Non-Indexed 
 
Citations, Ovid MEDLINE ® Daily and Ovid MEDLINE ® 1946 – Present 
 
Literature Search Strategy 
 
1. inflammatory arthritis.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, nm, kf, 
px, rx, an, ui, sy] 
 
2. rheumatoid arthritis.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, nm, kf, px, 
rx, an, ui, sy] 
 
3. immunisation.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, nm, kf, px, rx, an, 
ui, sy] 
 
4. vaccination.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, nm, kf, px, rx, an, 
ui, sy] 
 
5. vaccine.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, nm, kf, px, rx, an, ui, sy] 
 
6. influenza.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, nm, kf, px, rx, an, ui, 
sy] 
 
7. influenza vaccine.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, nm, kf, px, rx, 
an, ui, sy] 
 
8. pneumovax.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, nm, kf, px, rx, an, 
ui, sy] 
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9. pneumococcal vaccine.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, nm, kf, 
px, rx, an, ui, sy] 
 
10. prevenar.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, nm, kf, px, rx, an, ui, 
sy] 
 
11. 1 or 2 
 
12. 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
 
13. 11 and 12 
 
14. remove duplicates from 13 
 
15. limit 14 to english language 
 
16. limit 15 to human 
 
17. limit 16 to yr="2000 -Current 
